Deferasirox: An update

Hemoglobin

Volumn 33, Issue SUPPL. 1, 2009, Pages

  Porter, John B ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Chelation; Deferasirox; Iron overload

Indexed keywords

CREATININE; DEFERASIROX; FERRITIN; IRON;

AGRANULOCYTOSIS; ANEMIA; BLOOD TRANSFUSION; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; EXCRETION; FERRITIN BLOOD LEVEL; GASTROINTESTINAL DISEASE; HUMAN; IRON BALANCE; IRON BLOOD LEVEL; IRON OVERLOAD; NONHUMAN; PROSPECTIVE STUDY; SICKLE CELL ANEMIA; SIDE EFFECT; THALASSEMIA MAJOR; TREATMENT RESPONSE;

BENZOIC ACIDS; BLOOD TRANSFUSION; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MYOCARDIUM; TREATMENT OUTCOME; TRIAZOLES;

EID: 73949156661     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630260903347146     Document Type: Conference Paper

References (19)

1. Nick H, Acklin P, Lattmann R, et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem. 2003;10:1065-1076.
2. Hershko C, Konijn AM, Nick HP, Breuer W, Cabantchik ZI, Link G. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood. 2001;97:1115-1122.
3. Glickstein H, El RB, Link G, et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood. 2006;108:3195-3203.
4. Wood JC, Otto-Duessel M, Aguilar M, et al. Cardiac iron determines cardiac T2&, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation. 2005;112:535-543.
5. Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol. 2003;43:565-572.
6. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361:1597-1602.
7. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91:873-880
8. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107:3455-3462.
9. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136:501-508.
10. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in thalassemia major. Blood. 2008;111:583-587.
11. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80:168-176.
12. Cappellini M, Elalfy MS, Kattamis A, et al. Efficacy and safety of once-daily, oral iron chelator deferasirox (Exjade® ) in a large group of regularly transfused patients with b-thalassemia major. Blood. 2008;112:Abstract 3878.
13. Porter JB, Piga A, Cohen A, et al. Safety of deferasirox (Exjade(R)) in patients with transfusiondependent anemias and iron overload who achieve serum ferritin levels
14. Piga A, Kebaili K, Galanello R, et al. Cumulative efficacy and safety of 5-year deferasirox (Exjade® ) treatment in pediatric patients with thalassemia major: a phase II multicenter prospective trial 2008. Blood 2008;112 Abstract 5413.
15. Garbowski M, Eleftheriou P, Pennell D, Tanner M, Porter JB. Impact of compliance, ferritin and LIC on long-term trends in myocardial T2& with deferasirox. Blood. 2008;112:Abstract 116.
16. Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelation, in heavily iron-overloaded patients with b-thalassemia: the ESCALATOR study. Eur J Haematol. 2009;82:458-465.
17. Taher A, Cappellini D, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30 mg/d per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol. [Epub ahead of print].
18. Pennell D, Sutcharitchan P, El-Beshlawy A, et al. Efficacy and safety of deferasirox (Exjade® ) in preventing cardiac iron overload in b-thalassemia patients with normal baseline cardiac iron: results from the cardiac substudy of the EPIC trial. Blood. 2008;112:Abstract 3874.
19. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy and safety of deferasirox (Exjade® ) in reducing cardiac iron in patients with b-thalassemia major: results from the cardiac substudy of the EPIC trial. Blood. 2008;112:Abstract 3873.